Equillium is a biotechnology company leveraging deep understanding of immunobiology to develop products for autoimmune and inflammatory disorders, or immuno-inflammation, with high unmet medical need.
Our initial product candidate, EQ001, is a clinical stage first-in-class monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. CD6 plays a central role in effector T cell activity, which drives a number of immuno-inflammatory diseases such as graft versus host disease, asthma, uveitis, colitis, lupus and multiple sclerosis. We believe EQ001 may have broad therapeutic utility and our current pipeline is focused on developing EQ001 as a best-in-class treatment for multiple severe immuno-inflammatory disorders. We are based in La Jolla, CA, and have assembled an accomplished team that includes veterans in drug discovery, development and commercialization.
Chairman and Chief Executive Officer
President and Chief Business Officer
Chief Scientific Officer
Chief Medical Officer
Chief Financial Officer
Vice President of Operations
Vice President of Development Operations
Vice President of Commercial
Head of Regulatory Affairs
Director of Research
Head of CMC
Equillium acquired U.S. and Canadian rights to EQ001
through an exclusive collaboration and license agreement with Biocon.